RT期刊文章SR电子T1出现再灌注时间强烈确定临床结果在范围广泛的方面得分在血管内治疗缺血性中风(I6.0010)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP I6.0010 VO 86是16补充A1 Joon-Tae金正日A1玛雅Goyal A1康Pereira-Mendes A1阿兰Bonafe A1 Jan Gralla A1 R首页eza贾汗A1兰德利维A1大卫Liebeskind A1 Jeffrey节省年2016 UL //www.ez-admanager.com/content/86/16_Supplement/I6.0010.abstract AB目的:调查是否建立梗塞核心尺寸基线影像修改出现再灌注时间的关系功能结果在急性缺血性中风患者机械血栓切除术。背景:都出现再灌注(OTR)建立的时间和程度梗死预处理成像,阿尔伯塔省中风程序索引的早期CT尺度(方面),结果是重要的决定因素在急性缺血性中风。他们潜在的交互并没有被很好的描述。设计/方法:我们分析了Triple-S数据库,由个体患者数据汇集从3未来的纸牌支架猎犬试验和注册中心(迅速,迅速'明星)。入选标准是:治疗与纸牌设备和实现实质性的再灌注(TICI 2酮。三个月结果分析包括功能独立(0 - 2)夫人和自由从残疾夫人(0 - 1)。结果:在305例,平均年龄为66.9±12.6年,58 (percnt)女,署16.9±4.6。基线方面得分在7.6 (percnt) 5 - 6, 7 - 8在37.1 (percnt),和52.0 (percnt), 9 - 10和出现再灌注时间意味着297±95分钟。3个月,健康结果夫人(0 - 1)是在43.9 (percnt)和功能独立夫人(0 - 2)在60.1 [percnt]。之间的0 - 2的结果,夫人OTR乘以2到8个小时,好结果的时间点是更高的方面得分较高,但拒绝与类似的陡度。9 - 10的方面,好的结果率85.6 (percnt) OTR 2-3h和41.1 [percnt] OTR 7-8h。 OTR times associated with 50[percnt] of patients achieving mRS 0-2 were: 390m for ASPECTS 9-10, 330m for 7-8, and 260m for 6 or less. CONCLUSIONS: Patients with higher ASPECTS scores are more likely to have good clinical outcomes at all onset to reperfusion intervals. But from 2 hours on, benefit falls at a steep and even pace across all ASPECT categories, reinforcing the need to treat all patients as fast as possible.Disclosure: Dr. Kim has nothing to disclose. Dr. Goyal has nothing to disclose. Dr. Pereira-Mendes has received personal compensation for activities with Stryker. Dr. Bonafe has nothing to disclose. Dr. Gralla has nothing to disclose. Dr. Jahan has received personal compensation for activities with ev3 Inc. as a consultant. Dr. Levy has received royalty, license fee, or contractual rights payments from Intratech Medical Ltd. and Mynx/Access Closure. Dr. Liebeskind has received personal compensation for activities with Stryker and Covidien as a consultant. The University of California, Regents receive funding for Dr. Saver's services as a scientific consultant regarding trial design and conduct to BrainsGate, Covidien, Stryker, Boehringer Ingelheim (prevention only), and St. Jude Medical. Dr. Saver has receMonday, April 18 2016, 1:00 pm-5:30 pm